PERSONALIZED MOLECULARLY GUIDED MANAGEMENT OF ATOPIC DERMATITIS: PROGNOSTIC STRATIFICATION AND CLINICAL OUTCOMES IN A 300-PATIENT COHORT

Abstract

Precision management of atopic dermatitis may be  improved by integrating clinical severity, allergen components and FLG genotype.  Objective: To summarize outcomes of a personalized algorithm in patients with atopic  dermatitis. Methods: Aggregated findings from a 2022–2025 study of 150  personalized-care patients and 150 retrospective comparators were analyzed  descriptively. Results: A reported risk model achieved AUC 0.88, sensitivity 84.3%  and specificity 81.2%. Excellent immediate responses occurred in 14.7% versus 2.0%;  excellent longer-term outcomes in 29.3% versus 6.0%. Six-month sustained remission  was reported in 59.8% versus 31.2%. Conclusion: The findings suggest clinical utility  but warrant controlled evaluation and external validation.